The REVAMP trial: key questions remain - Authors' reply.

Autor: Pasricha SR; Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Diagnostic Haematology, The Royal Melbourne Hospital, Parkville, VIC, Australia; Clinical Haematology, The Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia. Electronic address: pasricha.s@wehi.edu.au., Moya E; Training and Research Unit of Excellence, Blantyre, Malawi; Department of Public Health, School of Public and Global Health, Kamuzu University of Health Sciences, Blantyre, Malawi., Ataide R; Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medicine at the Peter Doherty Institute, The University of Melbourne, Parkville, VIC, Australia., Mzembe G; Training and Research Unit of Excellence, Blantyre, Malawi; Department of Public Health, School of Public and Global Health, Kamuzu University of Health Sciences, Blantyre, Malawi., Harding R; Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia., Phiri K; Training and Research Unit of Excellence, Blantyre, Malawi; Department of Public Health, School of Public and Global Health, Kamuzu University of Health Sciences, Blantyre, Malawi.
Jazyk: angličtina
Zdroj: Lancet (London, England) [Lancet] 2024 Jan 06; Vol. 403 (10421), pp. 29-30.
DOI: 10.1016/S0140-6736(23)01915-3
Databáze: MEDLINE